The Swedish medtech company Kontigo Care is currently expanding its e-health platform Previct to private healthcare providers and occupational health services. - We will start selling in a few weeks or a month, says Alexander Stendahl to Finwire.Previously, the company was entirely focused on the Swedish public sector, primarily municipalities’ work in addiction and social care.- Most of the adaptation to the corporate market is done. The big task is to change contract models without losing revenue, says Alexander StendahlIn December, the company switched trading venue to Spotlight from First North.- We are a small company, and then the price difference matters.Kontigo Care operates in addiction care, relapse prevention, and related areas such as mental ill-health. The core is the digital e-health platform Previct, which is used as support between treatments and is based on continuous follow-up, digital testing, and data-driven insights for both care providers and users.- Addiction care is the big thing for us. The company now sees particularly strong potential in new use cases linked to workplaces and drug-free environments. One example is the company’s eye-scanning technology, which can indicate drug impairment.- We see significant upside there. In addiction care there is also a risk of other dependencies, for example alcohol. Tests can be packaged as an easy way for someone who wants to show that he or she no longer uses drugs.Kontigo Care is also working on new packaging of the knowledge the company has built up, including in risk assessments for companies.- We can do more and simpler tests for a drug-free work environment. We are now scaling for something new, where we are still looking at the pricing model, markets, and the first customers.The company expects to start sales in this segment within a few weeks to a month.The public sector remains the base, but the focus is broadening.- It is our core competence, but there is enormous potential around drug addiction in workplaces. If we find a model where we can scale the testing operation, the upside can be large. In parallel, dialogues are ongoing within corrections and forensic psychiatry, including internationally.- We will carry out pilot projects in the Netherlands, including with corrections. We will release more information about that soon.Strategic partnershipsThe company has initiated strategic partnerships with, among others, Feelgood in Sweden and Mehiläinen in Finland, which are seen as important for scaling the business in the Nordics and, in time, also outside the region.- They account for a small part of the business today, but with our new focus on drug-free workplaces they are very important. You can sell directly to companies with limited services, but there is reassurance for the customer in having occupational health services behind them if problems are found, and then getting clearer guidance on how to proceed.Kontigo Care is focusing primarily on the Nordics, where the company states it knows the markets well. The business model is mainly subscription-based.- Yes, subscriptions, but we sell capacity instead of individual licenses. That is a shift we have made.When it comes to targets, the company is cautious in the near term.- For 2026 we have very low targets. Internally we budget for 0–5 percent growth. The focus is on building products, partnerships, and sales channels. The goal is to become cash-positive after the first two quarters.At the same time, there is an ambition to grow faster over time.- We would like to grow by 10–20 percent and believe we can get there, but first we need to build out the platform.The Previct platform consists of several modules, including for alcohol, drugs, gambling addiction, mental health, and safety. Gambling addiction will be included as an add-on.The company offers a digital "check-up" for companies that do not work with drug testing today.- You perform tests in the app and answer a questionnaire that gives a risk score. For employers it is valuable to have carried out a risk assessment if something were to happen."Check-up" is about risk identification of the workplace, something all companies are required to have but few know how to implement and document.- A recurring risk score indicates the risk level for companies and can thereby say whether they have implemented sufficient measures, or should take the next step.Kontigo Care has registered the trademark "Dark Eye" and has a further roughly eight to nine patent applications pending.Dark-eye is a new patent to master the method also for people with darker eye color. - Dark eyes are more difficult for the technology to follow movement patterns, but we have nevertheless cracked the code for how to do it. This builds credibility and stability.However, decisions regarding all the patents may take time.- These are processes that are ongoing continuously and we receive updates continuously, but it can take up to two years before everything is complete.As for the competition, the company points to a clear difference compared to existing solutions.- There are many breath alcohol testers based on exhalation, but we are not aware of anyone else doing the same as we do with eye scanning. That technology is not commercially available on the market today.At the same time, the technology is considered to be well substantiated.- There have been many studies over the years. The challenges are, for example, lighting conditions and seeing the eye movements, but we do that quite well. Some types of drug use we identify beyond expectations; others are more difficult.The Netherlands has come the furthest in the field, where several hospitals are conducting clinical research.